The Psoriatic Arthritis clinical trial portfolio comprises approximately 139+ trials which are sponsored by various vendors. Interleukin inhibitors (42.31%) are the major mechanism of action of drugs which are under investigation in various development phases. Approximately 90-95% of clinical trials which are being under investigation as monotherapies therapies. Johnson & Johnson is the top sponsor for Psoriatic Arthritis-related ongoing clinical trials. Novartis AG, Amgen Inc, Bristol-Myers Squibb Co, and Pfizer Inc are among other notable clinical trial sponsors involved in Psoriatic Arthritis.

CHAPTER – 1: Psoriatic Arthritis Overview

CHAPTER – 2: Psoriatic Arthritis Epidemiology & Overview

CHAPTER - 3: Psoriatic Arthritis Market Size & Overview

CHAPTER – 4: Psoriatic Arthritis Marketed Drugs Overview

CHAPTER – 5: Psoriatic Arthritis Pipeline Drugs Overview

CHAPTER – 6: Psoriatic Arthritis Clinical Trials Overview

CHAPTER – 7: Psoriatic Arthritis Market Dynamics

CHAPTER – 8: Psoriatic Arthritis Competitive Landscape

CHAPTER – 9: Psoriatic Arthritis Miscellaneous